India's patents appeal board has dismissed British drugmaker AstraZeneca's petition challenging an earlier ruling that refused patent protection for a cancer-fighting drug, in the latest blow for Big Pharma in the country. The Indian patents office in 2007 refused patent protection to AstraZeneca's quinazoline molecule, citing lack of invention. The Intellectual Property Appellate Board (IPAB) on Monday upheld the refusal. The decision is a setback for struggling AstraZeneca, which is battling to turn itself around as key drugs lose patent protection.
FIRSTPOST. ARTICLES View all
FROM THE WEB.